Literature DB >> 2810119

Dihydropyridine calcium antagonists reduce the consumption of high-energy phosphates in the rat brain. A study using combined 31P/1H magnetic resonance spectroscopy and 31P saturation transfer.

M Rudin1, A Sauter.   

Abstract

The disappearance of high-energy phosphates (HEPs) in the rat brain during global ischemia induced by cardiac arrest is slowed down significantly by dihydropyridine Ca antagonists (DCAs) compared to controls. Two mechanisms might account for this effect: increased HEP production via anaerobic glycolysis or decreased HEP consumption. In order to obtain more insight into the underlying mechanisms of ATP preservation we have studied in the rat the effect of the DCAs isradipine, darodipine and nimodipine on the cerebral steady-state levels of HEPs and lactate as well as the intracellular pH value during global ischemia using combined 31P/1H magnetic resonance spectroscopy. We have found that the ATP preservation in DCA-treated animals is not associated with significantly higher postischemic lactate levels (lactate/N-acetylaspartate 0.97 +/- 0.08 for isradipine at a dose of 2.5 mg/kg i.p.) or lower pH values (6.40 +/- 0.03) as compared to control rats (lactate/N-acetylaspartate 0.94 +/- 0.13, pH = 6.49 +/- 0.03). This is in contrast to hyperglycemic rats, in which similar preservation of ATP levels during ischemia was observed; however, at the expense of a larger drop in brain pH (6.22 +/- 0.09) and a concomitant increase in cerebral lactate (lactate/N-acetylaspartate = 1.40 +/- 0.09). These results strongly favor reduced ATP consumption to be the cause for the protective effect of DCAs.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2810119

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Dynamic correlations between hemodynamic, metabolic, and neuronal responses to acute whole-brain ischemia.

Authors:  Jennifer M Taylor; Xiao-Hong Zhu; Yi Zhang; Wei Chen
Journal:  NMR Biomed       Date:  2015-09-16       Impact factor: 4.044

Review 2.  Experimental studies with isradipine in stroke.

Authors:  A Sauter; M Rudin
Journal:  Drugs       Date:  1990       Impact factor: 9.546

3.  Calcium antagonist isradipine reduces metabolic alterations in acute cerebral ischemia in spontaneously hypertensive rats.

Authors:  S Ibayashi; T Nagao; T Kitazono; H Ooboshi; J Kitayama; S Sadoshima; M Fujishima
Journal:  Neurochem Res       Date:  2000-03       Impact factor: 3.996

Review 4.  Creatine kinase in non-muscle tissues and cells.

Authors:  T Wallimann; W Hemmer
Journal:  Mol Cell Biochem       Date:  1994 Apr-May       Impact factor: 3.396

5.  Nimodipine does not affect the flow-metabolism couple in permanent cerebral ischemia.

Authors:  Shintaro Gomi; Mark G Burnett; Andrea Karp; Joel H Greenberg
Journal:  Exp Brain Res       Date:  2004-01-30       Impact factor: 1.972

Review 6.  Nimodipine. A review of its pharmacological properties, and therapeutic efficacy in cerebral disorders.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1992 Jul-Aug       Impact factor: 3.923

Review 7.  Interleaved and simultaneous multi-nuclear magnetic resonance in vivo. Review of principles, applications and potential.

Authors:  Alfredo L Lopez Kolkovsky; Pierre G Carlier; Benjamin Marty; Martin Meyerspeer
Journal:  NMR Biomed       Date:  2022-04-27       Impact factor: 4.478

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.